Genomes and Genes
- Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous ThromboembolismJ Emmerich
Hopital Europeen Georges Pompidou, Service de Medecine Vasculaire, Centre Claude Bernard et Laboratoire d Hémostase, Paris, France
Thromb Haemost 86:809-16. 2001..69). Conversely, factor II G20210A mutation was equally balanced in both patient groups...
- [Thrombophilia and pregnancy: which tests for which patients? The clinician's point of view]Joseph Emmerich
Service de Médecine Vasculaire et INSERM U428, Hopital Europeen Georges Pompidou, 20 40, rue Leblanc, 75908 Paris Cedex 15
Ann Med Interne (Paris) 154:345-53. 2003..When a laboratory work-up of thrombophilia is required, all the known causes of thrombophilia must be checked as none of them is specific of a single clinical feature, but also because they can be associated in the same patient...
- [Epidemiology of venous thrombosis]Joseph Emmerich
Service de Médecine Vasculaire HEGP et Unité INSERM U428, 20 40 rue Leblanc 75908 Paris
Bull Acad Natl Med 187:19-32; discussion 32-3. 2003..The association of several environmental or genetic and their analysis in the physiopathology of the disease and in the risk of recurrency is important in order to allow a better prevention of the disease and of its recurrencies...
- Infection and venous thrombosisJoseph Emmerich
Service de Médecine Vasculaire et HTA, Centre Claude Bernard de Recherche sur les Maladies Vasculaires, INSERM U428, University Paris 5, Paris, France
Pathophysiol Haemost Thromb 32:346-8. 2002..Other studies did not confirm such an association or found a lower odds ratio. This association remains to be confirmed in other case-control or prospective studies...
- [Frequency and risk factors of thrombo-embolic venous disease]Joseph Emmerich
Service de médecine vasculaire Hôpital européen Georges Pompidou et INSERM Unité 428 75908 Paris
Rev Prat 53:14-9. 2003..Association between cancer and venous thromboembolism has been recently studied, and is most often associated with a bad prognosis of the underlying cancer...
- Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit modelAnne Godier
Department of Anaesthesia and Critical Care, Paris Descartes University, Hotel Dieu University Hospital, Paris, France
Anesthesiology 116:94-102. 2012....
- Caution in interpreting results from imputation analysis when linkage disequilibrium extends over a large distance: a case study on venous thrombosisMarine Germain
INSERM UMR_S 937, ICAN Institute, Universite Pierre et Marie Curie, Paris, France
PLoS ONE 7:e38538. 2012..This variant was in fact the rs1799963, also known as the FII G20210A prothrombin mutation. This work may be of major interest not only for its scientific impact but also for its methodological findings...
- Early endothelial progenitor cells in bone marrow are a biomarker of cell therapy success in patients with critical limb ischemiaDavid M Smadja
Universite Paris Descartes, Paris, France Sorbonne Paris Cite, France
Cytotherapy 14:232-9. 2012....
- Efficacy of prothrombin complex concentrate to reverse the anticoagulant effect of the pentasaccharide fondaparinux in a rabbit modelAnne Godier
Department of Anesthesia and Critical Care, Paris Descartes University Hôtel Dieu, Paris, France
Thromb Haemost 105:161-8. 2011..EXTEM and FIBTEM tests were not modified. Regarding safety, PCC did not increase CFRs. PCC reduced bleeding without increasing thrombosis and was effective to reverse the haemorrhagic effect of fondaparinux in this rabbit model...
- Thrombospondin-1 is a plasmatic marker of peripheral arterial disease that modulates endothelial progenitor cell angiogenic propertiesDavid M Smadja
Universite Paris Descartes, Paris, France
Arterioscler Thromb Vasc Biol 31:551-9. 2011..We examined whether plasma levels of angiogenic factors are altered in plasma of patients with peripheral arterial disease (PAD) and whether these factors affect endothelial progenitor cell-induced angiogenesis...
- Venous thromboembolism: risk factors for recurrenceTienan Zhu
University Paris Descartes, INSERM U765, Service de Médecine Vasculaire HTA, Paris, France
Arterioscler Thromb Vasc Biol 29:298-310. 2009..Future studies are needed to refine the predictive value of known risk factors for VTE recurrence and to discover better markers...
- Bone marrow-derived mononuclear cell therapy induces distal angiogenesis after local injection in critical leg ischemiaJean Paul Duong Van Huyen
University Paris Descartes, Paris, France
Mod Pathol 21:837-46. 2008....
- P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control studyPierre Fontana
INSERM U 428, Hôpital Européen Georges Pompidou et Université Paris V, Paris, France
Circulation 108:2971-3. 2003..Because platelets play a key role in atherosclerosis and arterial thrombosis, we tested the possible link between the H2 haplotype and the risk of peripheral arterial disease (PAD) in a case-control study...
- Association of influenza vaccination with reduced risk of venous thromboembolismTienan Zhu
Deparment of Vascular Medicine, University Paris Decartes and INSERM U765, Paris, France
Thromb Haemost 102:1259-64. 2009..71, 95% CI, 0.53-0.94) and for both provoked (OR 0.71, 95% CI, 0.53-0.97) and unprovoked VTE (OR 0.85, 95% CI, 0.59-1.23). This case-control study suggests that influenza vaccination is associated with a reduced risk of VTE...
- Interleukin 8 is differently expressed and modulated by PAR-1 activation in early and late endothelial progenitor cellsDavid M Smadja
Universite Paris Descartes, Faculte de Pharmacie, Paris, France
J Cell Mol Med 13:2534-46. 2009..In conclusion, PAR-1 activation induces IL-8 synthesis by late EPC. This could potentially enhance cooperation between late and early EPC during neovascularization, through a paracrine effect...
- [Coagulation factor mutations and thrombosis]Martine Aiach
Service d Hematologie Biologique, Hopital Europeen Georges Pompidou, 20, rue Leblanc, 75908 Paris Cedex 15, France
Med Sci (Paris) 22:985-9. 2006..The exposition to acquired risk factors such as estrogen based oral contraception may also have a synergistic effect favoring thrombosis in patients with FV Leiden or other genetic risk factors...
- Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approachDavid Alexandre Tregouet
INSERM, Unite Mixte de Recherche S, Paris, France
Blood 113:5298-303. 2009..However, using this large cohort of subjects, we were able to replicate the mild effects of 2 nonsynonymous SNPs, rs1613662 in GP6 and rs13146272 in CYP4V2, recently suspected to be associated with VTE...
- [Treatment perspectives for critical limb ischemia: gene and cell therapy]Elisa Pasqualoni
Service de Médecine Vasculaire HTA, Hopital Europeen Georges Pompidou, F75908 Paris Cedex 15, France
Presse Med 37:1039-46. 2008..These innovative approaches appear both feasible and safe. Large randomized clinical trials are necessary to demonstrate their benefits and long-term safety...
- Genetics of venous thrombosis: insights from a new genome wide association studyMarine Germain
INSERM UMR_S 937 ICAN Institute, Universite Pierre et Marie Curie, Paris 6, Paris, France
PLoS ONE 6:e25581. 2011..Genetics factors are known to contribute to the susceptibility of the disease but how many genes are involved and their contribution to VT risk still remain obscure. We aimed to identify genetic variants associated with VT risk...
- Role of fibrinolysis and interventional therapy for acute venous thromboembolismJoseph Emmerich
University Paris Descartes, Hopital Europeen Georges Pompidou, Paris, France
Thromb Haemost 96:251-7. 2006....
- Cleaved protein S (PS), total PS, free PS, and activated protein C cofactor activity as risk factors for venous thromboembolismDelphine Borgel
Service d Hématologie Biologique A, Hopital Europeen Georges Pompidou, AP HP, Paris, France
Clin Chem 49:575-80. 2003..To clarify this issue, we designed a case-control study to evaluate the role of different molecular forms of plasma PS...
- The -33T-->C polymorphism in intron 7 of the TFPI gene influences the risk of venous thromboembolism, independently of the factor V Leiden and prothrombin mutationsNejma Ameziane
INSERM 479, Faculte Xavier Bichat, Paris, France
Thromb Haemost 88:195-9. 2002..These results suggest that the CC genotype of the TFPI intron 7 polymorphism is an independent protective factor for venous thromboembolism, an effect probably mediated by increased TFPI levels...
- The TF-603A/G gene promoter polymorphism and circulating monocyte tissue factor gene expression in healthy volunteersJean Luc Reny
Service d Hématologie Biologique A, Hôpital Européen Georges Pompidou INSERM Unité 428, Paris, France
Thromb Haemost 91:248-54. 2004..The TF-603A/G gene promoter polymorphism thus significantly influences constitutive TF gene expression in human monocytes but has no major effect on TF gene expression or on WBCT in LPS stimulated conditions...
- A two adenine insertion polymorphism in the 3' untranslated region of factor VII gene is associated with peripheral arterial disease but not with venous thrombosis. Results of case-control studiesEmilie Serve
INSERM, Unité 765, Paris, France
Thromb Haemost 98:733-7. 2007..24 [95% CI 0.06-0.99]. In conclusion, the 2 adenine insertion in the 3'UTR of FVII gene, related to lower plasma FVII levels, is a genetic variation that may contribute to reduce the risk of PAD...
- Development of a novel immunoassay for the assessment of plasma Gas6 concentrations and their variation with hormonal statusSylvain Clauser
Assistance Publique Hopitaux de Paris, Hopital Europeen Georges Pompidou, Service d Hématologie Biologique A, Paris, France
Clin Chem 53:1808-13. 2007..We report the development and validation of an ELISA for Gas6, and the variation of plasma Gas6 with hormonal status in a study designed to evaluate the effect of oral contraception on plasma markers...
- [Stem cells and cardiovascular therapy: results in peripheral artery disease]Joseph Emmerich
Medecine vasculaire, HTA, HEPG, 20 rue Leblanc, 75908 Paris Cedex 15, Universite Paris Descartes, IFR Necker Enfants Malades, Paris, France, INSERM U765
Bull Acad Natl Med 193:549-57; discussion 557-8. 2009..Several teams are also testing allogeneic stem cells and autologous progenitor endothelial cells for the treatment of peripheral artery disease but they are encountering significant hurdles...
- Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrelClemence Hindy-François
INSERM UMRS 765, Pharmaceutical Sciences University, Paris, France
Thromb Haemost 104:823-30. 2010..These effects were unaffected by either rFVIIa dose. rFVIIa accelerated thrombin generation but had no effect on platelet aggregation in citrated platelet-rich plasma. rFVIIa did not modify HS blood loss associated with cAPA in rabbits...
- Alpha1-antitrypsin gene polymorphisms are not associated with renal arterial fibromuscular dysplasiaJérôme Perdu
Assistance Publique Hopitaux de Paris, Hopital Europeen Georges Pompidou, Department of Medical Genetics, Paris, France
J Hypertens 24:705-10. 2006..Case reports have associated alpha1-antitrypsin deficiency and FMD. The aim of this study was to test the implication of the alpha1-antitrypsin (AAT) gene in a large cohort of patients with renal FMD...
- Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global SurveyJean Francois Bergmann
Hopital Lariboisiere, University Paris 7, Paris, France
Thromb Haemost 103:736-48. 2010..These data support the necessity to improve implementation of available guidelines for evaluating VTE risk and providing prophylaxis to hospitalised medical patients...
- The type of variants at the COL3A1 gene associates with the phenotype and severity of vascular Ehlers-Danlos syndromeMichael Frank
AP HP, Hopital Europeen Georges Pompidou, Département de génétique, Service de Médecine Vasculaire et Centre de Référence des Maladies Vasculaires Rares, Paris, France
Eur J Hum Genet 23:1657-64. 2015..These findings may help refine diagnostic strategy, genetic counselling and clinical care. ..
- Association of Takayasu's arteritis and Crohn's disease. Results of a study on 44 Takayasu patients and review of the literatureJean Luc Reny
Service de Medecine Vasculaire, Hopital Europeen Georges Pompidou, 75908 Paris Cedex 15
Ann Med Interne (Paris) 154:85-90. 2003..Our results and previous reports suggest that this association of rare diseases is not fortuitous. With respect to the indolent course of Takayasu's arteritis, early diagnosis of vascular lesions in Crohn patients is encouraged...
- [How to manage Takayasu arteritis?]Tristan Mirault
Pôle Cardiovasculaire, Hopital Europeen Georges Pompidou, Universite Paris Descartes, Unité de médecine vasculaire, Paris, France
Presse Med 41:975-85. 2012..Monitoring of therapy should be clinical and supported by biological markers and imaging. Reconstructive surgery should be performed in the quiescent phase of disease...
- Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trialKim Thanh Ong
Assistance Publique, Hopitaux de Paris, Hopital Europeen Georges Pompidou, Paris, France
Lancet 376:1476-84. 2010..Our aim was to assess the ability of celiprolol, a β(1)-adrenoceptor antagonist with a β(2)-adrenoceptor agonist action, to prevent arterial dissections and ruptures in vascular Ehlers-Danlos syndrome...
- Residual pulmonary vascular obstruction and recurrence after acute pulmonary embolism. A single center cohort studyBenjamin Planquette
Universite Paris Descartes, Sorbonne Paris Cité, France Service de pneumologie et soins intensifs, Service de Pneumologie et Soins Intensifs, Hopital Europeen Georges Pompidou, AP HP, Paris, France INSERM UMR S 1140, Paris, France Electronic address
Thromb Res 148:70-75. 2016..The risk of recurrence in patients with RPVO remains unknown. The present study aims to assess the risk of recurrent venous thromboembolism (VTE) in patients with RPVO after a first symptomatic episode of PE...
- Carotid stiffness change over the cardiac cycle by ultrafast ultrasound imaging in healthy volunteers and vascular Ehlers-Danlos syndromeTristan Mirault
aService de Médecine Vasculaire, Hopital Europeen Georges Pompidou, Pôle Cardiovasculaire bCentre de Référence National Maladies Vasculaires Rares, Hopital Europeen Georges Pompidou, Assistance Publique Hopitaux de Paris APHP, Universite Paris Descartes, Sorbonne Paris Cité, PARCC cInstitut Langevin Ondes et Images, ESPCI ParisTech, CNRS UMR 7587, INSERM, Paris dSuperSonic Imagine, Aix en Provence eCentre d Investigation Clinique, Hopital Europeen Georges Pompidou, Assistance Publique Hopitaux de Paris APHP, Universite Paris Descartes, Sorbonne Paris Cité, Paris, France Tristan Mirault and Mathieu Pernot contributed equally to the writing of this article
J Hypertens 33:1890-6; discussion 1896. 2015..Our goal was to characterize the carotid diastolic-systolic arterial stiffening using ultrafast ultrasound imaging in healthy individuals and in vascular Ehlers-Danlos syndrome (vEDS), in which collagen type III is defectuous...
- Anti TNF-α in refractory Takayasu's arteritis: cases series and review of the literatureCloé Comarmond
Department of Internal Medicine French Reference Center for Rare Auto immune diseases Groupe hospitalier Pitié Salpêtrière, AP HP, 47 83 Bd de l Hopital, 75013, Paris, France
Autoimmun Rev 11:678-84. 2012..Further studies are warranted to assess the long term efficacy and safety of anti-TNF in TA and to better define if they should be prescribed earlier in the course of TA...
- Detection and characterisation of large SERPINC1 deletions in type I inherited antithrombin deficiencyVeronique Picard
Service d Hematologie Biologique, AP HP, Hopital Europeen Georges Pompidou, 75908 Paris Cedex 15, France
Hum Genet 127:45-53. 2010..Distinct mutational mechanisms explaining these Alu sequence-related deletions are proposed. Overall, in this series, large deletions detected by MLPA explain almost half of otherwise unexplained type I AT-inherited deficiency cases...
- Current state and perspective on medical treatment of critical leg ischemia: gene and cell therapyJoseph Emmerich
University Paris Descartes, Department of Vascular Medicine and Hypertension, Hopital Europeen Georges Pompidou, Paris
Int J Low Extrem Wounds 4:234-41. 2005..These studies demonstrated the short-term safety and feasibility of these new approaches, but larger randomized studies remain necessary to demonstrate their clinical benefits and longterm safety...
- [Cellular therapy in atherosclerotic arteriopathies: is there hope for those with severe prognosis?]Joseph Emmerich
Service de medicine vasculaire HTA et Inserm U428, Hopital Europeen Georges Pompidou, 75908 Paris Cedex 15
Rev Prat 55:1201-2. 2005
- Initial treatment of venous thromboembolismCecilia Becattini
Division of Internal and Cardiovascular Medicine, Department of Internal Medicine, University of Perugia, Italy
Thromb Haemost 96:242-50. 2006..An oral anticoagulant agent to be used without laboratory monitoring for both acute and long-term treatment of VTE remains an unsolved clinical need in the treatment of VTE...
- Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administrationCeline Straczek
INSERM, Cardiovascular Epidemiology Unit, Villejuif, France
Circulation 112:3495-500. 2005..Transdermal estrogen may be safe with respect to VTE. We investigated the impact of the route of estrogen administration on the association between a prothrombotic mutation (factor V Leiden or prothrombin G20210A mutation) and VTE risk...
- Prothrombin 20210G>A is an ancestral prothrombotic mutation that occurred in whites approximately 24,000 years agoAriella Zivelin
The Amalia Biron Research Institute of Thrombosis and Hemostasis, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel
Blood 107:4666-8. 2006....
- Uptake of new treatment strategies for deep vein thrombosis: an international auditDrahomir A Aujesky
University of Lausanne
Int J Qual Health Care 16:193-200. 2004....
- Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER studyMarianne Canonico
INSERM Unit 780, Cardiovascular Epidemiology Section, 16 Avenue Paul Vaillant Couturier, 94807 Villejuif Cedex, France
Circulation 115:840-5. 2007..Transdermal estrogen may be safer. However, currently available data have limited the ability to investigate the wide variety of types of progestogen...
- [How to assess thrombophilia and which one?]Joseph Emmerich
Service de medecine vascularie, HTA et unite Inserm U765, Universite Paris Descartes, Hopital Europeen Georges Pompidou, 75980 Paris Cedex 15
Rev Prat 57:714-5. 2007
- [Risk factors of the recurrence of venous thromboembolism]Joseph Emmerich
Rev Prat 57:717-8. 2007
- A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosisBeatrice Saposnik
INSERM U 428, 4 avenue de l Observatoire, 75006 Paris, France
Blood 103:1311-8. 2004..8; P =.004). Thus, the A3 haplotype, which is associated with elevated plasma sEPCR levels, is a candidate risk factor for venous thrombosis...
- Can fishing for new genes catch patients at risk of coronary artery disease?Joseph Emmerich
Clin Chem 54:453-5. 2008
- Purinergic receptor P2Y, G-protein coupled, 12 gene variants and risk of incident ischemic stroke, myocardial infarction, and venous thromboembolismRobert Y L Zee
Laboratory of Genetic and Molecular Epidemiology, Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medial School, 900 CommonwealthAvenue East, Boston, MA 02215, USA
Atherosclerosis 197:694-9. 2008..The present investigation provides evidence for an association of the P2RY12 haplotype H2 with lower risk of DVT/PE; however these findings require replication in other well-designed studies...
- No clear link between VKORC1 genetic polymorphism and the risk of venous thrombosis or peripheral arterial diseaseDavid M Smadja
Thromb Haemost 99:970-2. 2008
- Residual venous thrombosis and recurrent thromboembolismJoseph Emmerich
Ann Intern Med 139:303; author reply 304. 2003
- Antithrombin Cambridge II (A384S): prevalence in patients of the Paris Thrombosis Study (PATHROS)Veronique Picard
Blood 110:2777-8. 2007
- Paraneoplastic acral vascular syndrome: epidemiologic features, clinical manifestations, and disease sequelaeEwa Poszepczynska-Guigné
Department of Dermatology, Hopital Saint Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
J Am Acad Dermatol 47:47-52. 2002..Acral vascular syndromes associated with malignancy have rarely been reported...
- [Medical treatment of critical leg ischemia: current status and future perspectives of gene and cell therapy]Joseph Emmerich
Universite Paris Descartes, INSERM U765, Service de Médecine Vasculaire HTA, Hopital Europeen Georges Pompidou, 20 rue Leblanc, 75908 Paris 15
Bull Acad Natl Med 190:667-80; discussion 680-1, 683-4. 2006..These approaches appear to be feasible and safe in the short-term, but large randomized studies are necessary to demonstrate their clinical benefits and long-term safety...
- Evaluating chronic venous disease with a new venous severity scoring systemMichael A Ricci
Department of Surgery, Vermont College of Medicine, Burlington, 05405 0068, USA
J Vasc Surg 38:909-15. 2003..However, validation of the VCSS against an objective test is lacking. The purpose of this study was to test the VCSS against abnormalities found on venous ultrasound (US) scans...
- Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemiaSigrid Nikol
Department of Cardiology and Angiology, Universitatsklinikum, Munster, Germany
Mol Ther 16:972-8. 2008..In patients with CLI, plasmid-based NV1FGF gene transfer was well tolerated, and resulted in a significantly reduced risk of major amputation when compared with placebo...